After announcing it was raising a $6M Series A last March, Curi Bio Inc., a Seattle life science startup has closed a $10M Series A round.
The Washington-based company develops stem cell-based platforms for drug discovery in an effort to close the gap between preclinical studies results and clinical setting.
“This funding validates the need for more predictive and mature human stem cell platforms to close the gap between preclinical results and clinical outcomes,” said Michael Cho, CEO of Curi Bio in a March release announcing the first portion of the funding.